Tafamidis treats transthyretin amyloid cardiomyopathy

September 18, 2018

(HealthDay)—In patients with transthyretin amyloid cardiomyopathy, treatment with tafamidis reduces all-cause mortality and cardiovascular-related hospitalizations versus placebo, according to a study published in the Sept. 13 issue of the New England Journal of Medicine.

Mathew S. Maurer, M.D., from Columbia University in New York City, and colleagues randomly assigned 441 patients with transthyretin amyloid cardiomyopathy in a 2:1:2 ratio to receive tafamidis 80 mg, tafamidis 20 mg, or placebo for 30 months.

The researchers found that all-cause mortality (hazard ratio, 0.7) and rates of cardiovascular-related hospitalizations (relative risk ratio, 0.68) were lower among the 264 patients who received tafamidis than the 177 patients who received placebo. Tafamidis was also associated with a lower rate of decline in distance for the six-minute walk test and a lower rate of decline in Kansas City Cardiomyopathy Questionnaire-Overall Summary score at month 30. Incidence and types of adverse events were similar between the two groups.

"In with transthyretin amyloid , tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the in functional capacity and quality of life as compared with ," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which funded the study.

Explore further: Drug reduces deaths and hospitalizations from underdiagnosed form of heart failure

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Drug reduces deaths and hospitalizations from underdiagnosed form of heart failure

August 27, 2018
A phase three clinical trial has shown that a drug called tafamidis significantly reduces deaths and hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive form of heart failure that ...

Researchers discover first treatment to improve survival in rare heart condition

August 27, 2018
Tafamidis is the first treatment to improve survival and reduce hospitalisations in a rare heart condition called transthyretin amyloid cardiomyopathy, according to late breaking research presented today in a Hot Line Session ...

Patisiran, inotersen aid hereditary transthyretin amyloidosis

July 6, 2018
(HealthDay)—For patients with hereditary transthyretin amyloidosis with polyneuropathy, an investigational RNA interference therapeutic agent (patisiran) and a 2'-O-methoxyethyl-modified antisense oligonucleotide (inotersen), ...

Escitalopram cuts MACE risk in depressed patients with ACS

July 25, 2018
(HealthDay)—For patients with depression following recent acute coronary syndrome (ACS), escitalopram results in lower risk of major adverse cardiac events (MACE) versus placebo, according to a study published in the July ...

Worse health status with shorter telomere length in COPD

September 13, 2018
(HealthDay)—Patients with chronic obstructive pulmonary disease (COPD) with shorter telomere length have worse health status, according to a study published in the August issue of CHEST.

Tafamidis: Approval denotes proven added benefit

September 17, 2012
Tafamidis meglumine (trade name: Vyndaqel) was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder ("orphan disease") is caused by a defective gene and is associated with ...

Recommended for you

Novel genetic study sheds new light on risk of heart attack

October 12, 2018
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.

Researchers say ritual for orthodox Jewish men may offer heart benefits

October 11, 2018
A pilot study led by researchers at the University of Cincinnati (UC) College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

Seed oils are best for LDL cholesterol

October 9, 2018
If you want to lower your low-density lipoprotein cholesterol, called LDL or, colloquially, "bad cholesterol," the research is clear about one thing: You should exchange saturated fats with unsaturated fat. If you want to ...

Micropeptide restores heart function in mice

October 9, 2018
Researchers have discovered a micropeptide molecule that can restore normal heart function in mice, according to a study in eLife.

New risk test for sepsis for heart patients

October 5, 2018
Nearly one in four deaths in people with heart failure are caused by sepsis, according to new research.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.